Augulab-625 (Amoxycillin and Potassium Clavulanate Tablets I.P.)
Overview Service
Hizid-N is a fixed-dose combination antiretroviral therapy (ART) used in the treatment of HIV-1 infection. It combines three active ingredients:
Lamivudine – a nucleoside reverse transcriptase inhibitor (NRTI)
Zidovudine – another NRTI
Nevirapine – a non-nucleoside reverse transcriptase inhibitor (NNRTI)
Together, they help prevent the replication of the HIV virus and reduce viral load in the blood.
- Convenient once or twice daily dosing
- Triple-drug combination in a single tablet
- WHO-recommended combination for first-line ART in resource-limited settings
- Reduces the risk of HIV progression and transmission
- Manufactured under strict pharmaceutical standards (IP grade)
Uses / Indications
- Treatment of HIV-1 infection in adults and children weighing ≥25 kg
- Used as part of a comprehensive antiretroviral regimen
- Helps to delay disease progression to AIDS
- Reduces viral load and increases CD4 (T-cell) count
Dosage & Administration
- 1 tablet twice daily (after an initial lead-in period for Nevirapine if required)
- Nevirapine requires dose escalation (200 mg once daily for 14 days) to reduce the risk of rash
- Do not skip doses – adherence is critical to prevent resistance
- May be taken with or without food
- Regular monitoring of liver enzymes and hematologic profile is necessary
Precautions
- Hepatotoxicity (especially from Nevirapine) – monitor liver function regularly
- Severe skin reactions like Stevens-Johnson Syndrome – discontinue immediately if rash appears
- Lactic acidosis and hepatomegaly – rare but potentially fatal side effects of Lamivudine and Zidovudine
- Anemia and neutropenia – monitor complete blood count (CBC)
